Navigation Links
Intera 3.0T

ProductsIntera 3.0T
Company Philips Medical Systems
Item Intera 3.0T
Features Compact footprint, short-bore design. Intera-optimized 3.0T whole body applications. Advanced SENSE technology. Unmatched platform longevity. Embodies the newest technology, bringing the power of 3.0T into a clinically practical, patient friendly design. Real-time MR scanning thanks to Philips real-time spectrometer. Advanced spectroscopy package. Interactive real-time scanning. Patient friendly, open design with the ultra-short 1.57 m magnet and wide 60 cm patient opening. Fully integrated into the New Intera family, sharing it's proven platform of world-renowned performance, speed and ease of use. Sitting is simple and cost-effective: lightweight (only 5500 kg, half as much as other 3.0T systems) and compact footprint (same as our 1.5T system)
Description Intera 3.0T is the most compact high-field clinical whole-body MR system in the world, bringing 3.0T capabilities "out of the tunnel" and into the light of an open, patient-friendly design.
Info Philips Medical SystemsCall Philips Medical Systems to buy products (US and Canada only; other locations use number below) USACanada1-866-745-0519

Customer Service: 1-800-722-7900

Related medicine products :

1. Concise Guide to Drug Interaction Principles for Medical Practice
2. Drug Facts - Gold (A to Z Drugs and Drug Interaction)
3. Drug Interaction Facts: Herbal Supplements & Food
4. The Medical Letters Handbook of Adverse Drug Interactions
5. Drug Facts - Platinum (A to Z, Natural Products and Drug Interaction)
6. iFacts™: Drug Interaction Facts
TAG: Intera
Other Medicine News:Health News:Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 2Health News:Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 3Health News:Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 4Health News:Garry W. Rogerson Elected Chairman of the Board of Varian, Inc. 2Health News:Smokers Will Stop for Their Pet's Sake 2Health News:Diseased Heart Valve Replaced Through Small Chest Incision 2Health News:Diseased Heart Valve Replaced Through Small Chest Incision 3Health News:Diseased Heart Valve Replaced Through Small Chest Incision 4Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 2Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 3Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 4Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 5Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 6Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 7Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 8Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 9Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 10Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 11Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 12Health News:Shaklee Hits the Road with its Infinite Possibilities Tour in New York, NY 2
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Within3 Expands into Mobile Applications 2Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 1Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 2Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 3Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 4Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 5Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 1Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 2Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 3Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 5Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 6Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 1Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 2Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 3Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 4